WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and Synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis 04 August 2015
Pfizer's Centers for Therapeutic Innovation and Jeffrey Modell Foundation announce collaboration 13 July 2015
Pfizer enters into agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline 23 June 2015
Get Ready. Get Set. Get Old. 04 June 2015
Pfizer announces $3 million grants program to further clinical research in advanced breast cancer 28 May 2015
Pfizer acquires minority interest in AM-Pharma; secures option to acquire company 11 May 2015
Pfizer and Lilly preparing to resume Phase 3 chronic pain program for Tanezumab 23 March 2015
Pfizer to Acquire Hospira 06 February 2015
Acquisition provides Pfizer with a preclinical CMV vaccine candidate 09 January 2015
Pfizer expands rare disease research with establishment of gene therapy platform 08 December 2014
Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study 30 September 2014
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen 26 August 2014
Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines 31 July 2014
Pfizer to Acquire InnoPharma, Inc. 16 July 2014
CliniWorks forms a strategic alliance with Pfizer 10 July 2014
James C. Smith elected to Pfizer's Board of Directors 26 June 2014
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration 18 June 2014
Pfizer opens new state-of-the-Art research and development site in Cambridge, Massachusetts 16 June 2014
Pfizer and the Avon Foundation for Women announce $1 million grants program 29 May 2014
Pfizer brings frequent heartburn relief OTC with new Nexium® 24HR 27 May 2014
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.